Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Pfizer
M.D. Anderson Cancer Center
Erasca, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Arvinas Inc.
University of Colorado, Denver
Pfizer
Eli Lilly and Company
Bayer
Eli Lilly and Company
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Ikena Oncology
Eli Lilly and Company
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Turning Point Therapeutics, Inc.
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Instituto do Cancer do Estado de São Paulo
Columbia University
Eli Lilly and Company
Theratechnologies
Xynomic Pharmaceuticals, Inc.
Cedars-Sinai Medical Center
Rutgers, The State University of New Jersey
Sotio Biotech Inc.
Salubris Biotherapeutics Inc
NantCell, Inc.
Turning Point Therapeutics, Inc.
ABM Therapeutics Corporation
TransThera Sciences (Nanjing), Inc.
Istituti Clinici Scientifici Maugeri SpA
M.D. Anderson Cancer Center
Kineta Inc.
Institut Bergonié
Blue Note Therapeutics
MacroGenics
Dana-Farber Cancer Institute
Fore Biotherapeutics
Celgene
Pfizer
Amgen
Centre Hospitalier Universitaire de Nice
SWOG Cancer Research Network
AHS Cancer Control Alberta